CoChat

Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant

Open access

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Abstract

Colorectal cancer is a molecularly heterogeneous disease. Responses to genotoxic chemotherapy in the adjuvant or palliative setting vary greatly between patients, and colorectal cancer cells often resist chemotherapy by evading apoptosis. Antagonists of an inhibitor of apoptosis proteins (IAPs) can restore defective apoptosis signaling by degrading cIAP1 and cIAP2 proteins and by inhibition of XIAP. Due to the multiple molecular mechanisms-of-action of these targets, responses to IAP antagonist may differ between molecularly distinct colon cancer cells. In this study, responses to the IAP antagonist Birinapant and oxaliplatin/5-fluorouracil (5-FU) were investigated in 14 colon cancer cell lines, representing the consensus molecular subtypes (CMS). Treatment with Birinapant alone did not result in a substantial increase in apoptotic cells in this cell line panel. Annexin-V/PI assays quantified by flow cytometry and high-content screening showed that Birinapant increased responses of CMS1 and partially CMS3 cell lines to oxaliplatin/5-FU, whereas CMS2 cells were not effectively sensitized. FRET-based imaging of caspase-8 and -3 activation validated these differences at the single-cell level, with CMS1 cells displaying sustained activation of caspase-8-like activity during Birinapant and oxaliplatin/5-FU co-treatment, ultimately activating the intrinsic mitochondrial apoptosis pathway. In CMS2 cell lines, Birinapant exhibited synergistic effects in combination with TNFα, suggesting that Birinapant can restore extrinsic apoptosis signaling in the context of inflammatory signals in this subtype. To explore this further, we co-cultured CMS2 and CMS1 colon cancer cells with peripheral blood mononuclear cells. We observed increased cell death during Birinapant single treatment in these co-cultures, which was abrogated by anti-TNFα-neutralizing antibodies. Collectively, our study demonstrates that IAP inhibition is a promising modulator of response to oxaliplatin/5-FU in colorectal cancers of the CMS1 subtype, and may show promise as in the CMS2 subtype, suggesting that molecular subtyping may aid as a patient stratification tool for IAP antagonists in this disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-020-03232-z

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Response to Birinapant treatments in colon cancer cell lines. A HCT116, LS1034, LS513, and MDST8 cells were treated for 24 h and 48 h with the indicated treatments. The colored bars represent the subtype of the cell lines (CMS1—orange; CMS2—blue; CMS3—pink; CMS4—green). Blots were probed for cIAP1, cIAP2, and XIAP as well as the cleaved forms of caspase-3, -7, and -8. B–D All cell lines were treated for 48 h with 10 ng/ml TNFα, 1 µM Birinapant, 2 µM oxaliplatin/ 10 µM 5-FU (Oxa/5-FU) or a combination of these drugs. B Gating strategy for apoptosis assay. Only the sum of necrotic, early-, and late-apoptotic cells are shown in C and D. C Combined treatment results of all cell lines by CMS subtype. To normalize cell line intrinsic cell death, the background cell death (DMSO control) was subtracted. A two-way ANOVA was performed, excluding the CMS4 subtype. A Tukey’s test for multiple comparisons was used for post hoc analysis. D Treatment outcomes per cell line (mean + SD), grouped by their subtypes. To highlight the effects of Birinapant only, the single treatments and their corresponding co-treatment with Birinapant are shown. N = 3; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
Fig. 1 Response to Birinapant treatments in colon cancer cell lines. A HCT116, LS1034, LS513, and MDST8 cells were treated for 24 h and 48 h with the indicated treatments. The colored bars represent the subtype of the cell lines (CMS1—orange; CMS2—blue; CMS3—pink; CMS4—green). Blots were probed for cIAP1, cIAP2, and XIAP as well as the cleaved forms of caspase-3, -7, and -8. B–D All cell lines were treated for 48 h with 10 ng/ml TNFα, 1 µM Birinapant, 2 µM oxaliplatin/ 10 µM 5-FU (Oxa/5-FU) or a combination of these drugs. B Gating strategy for apoptosis assay. Only the sum of necrotic, early-, and late-apoptotic cells are shown in C and D. C Combined treatment results of all cell lines by CMS subtype. To normalize cell line intrinsic cell death, the background cell death (DMSO control) was subtracted. A two-way ANOVA was performed, excluding the CMS4 subtype. A Tukey’s test for multiple comparisons was used for post hoc analysis. D Treatment outcomes per cell line (mean + SD), grouped by their subtypes. To highlight the effects of Birinapant only, the single treatments and their corresponding co-treatment with Birinapant are shown. N = 3; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.CC BY · PubMed Central
Fig. 2 Cluster analysis of treatment outcomes. A hierarchically clustered heatmap was generated using the complete Euclidean distance method with normalized amount of cell viability after 48 h treatment. The first row represents the CMS of the respective cell lines and the KRAS, BRAF, p53 mutational status as well as the microsatellite stability (MSS/MSI) of the cell lines. For cell lines labeled with an asterisk, viability was assessed by an Annexin-V/PI assay using high-content-screening. For all other cell lines, viability was determined by flow cytometry.
Fig. 2 Cluster analysis of treatment outcomes. A hierarchically clustered heatmap was generated using the complete Euclidean distance method with normalized amount of cell viability after 48 h treatment. The first row represents the CMS of the respective cell lines and the KRAS, BRAF, p53 mutational status as well as the microsatellite stability (MSS/MSI) of the cell lines. For cell lines labeled with an asterisk, viability was assessed by an Annexin-V/PI assay using high-content-screening. For all other cell lines, viability was determined by flow cytometry.CC BY · PubMed Central
Fig. 3 CMS subtypes show distinct differences in caspase activation kinetics in response to co-treatment of Birinapant and chemotherapy. A, B Representative time-lapse images of Venus, TMRM and CFP/FRET emission ratio in HCT116 (A) cells stably expressing IETD-FRET probe (B) treated with 2 µM oxaliplatin/10 µM 5-FU/1 µM Birinapant for 48 h. Scale bar: 20 µm. C Overview of generation and interpretation of a single-cell trace extracted from time-lapse imaging of IETD-FRET probe cleavage in an HCT116 cell showing features of apoptosis in response to combination treatment. Cleavage of IETD substrate by caspases results in a disruption in FRET signal, which can be quantified by measuring CFP/FRET emission ratio. A mild increase in CFP/FRET emission ratio (I) before the loss of TMRM signal due to MOMP (II, red dashed line) indicates caspase-8-like activity (I–II, color coded as light blue). A rapid increase in CFP/FRET emission ratio (III) after the loss of TMRM signal indicates the involvement of executioner caspases (caspase-3 and -6) (II–III, color coded as light brown). D, E Representative single-cell CFP/FRET emission ratio kinetics of HCT116 (CMS1), RKO (CMS1), GP5D (CMS2), LS1034 (CMS2), LS513 (CMS3), and MDST8 (CMS4) cell lines treated with Oxa/5-FU, Birinapant, or combination of the drugs (D). Summary of the differences in caspase activation kinetics among CMS in response to co-treatment of Oxa/5-FU and Birinapant (E). F Quantification and comparison of the differences in caspase activation kinetics among CMS in response to Oxa/5-FU (left), Birinapant (middle), or combination of the drugs (right). “Onset of IETD cleavage” indicates a point of time at which cells start cleaving IETD substrate, “Duration of IETD cleavage” refers to a period of time between onset and end of IETD cleavage. Data are shown as individual values for each cell as well as the median ± quartiles. n = 146 cells were analyzed from at least three experiments per cell line. Statistical significance was tested using one-way ANOVA followed by Tukey’s multiple comparison test. “no substrate cleavage” indicates that cells did not exhibit an increase in IETD cleavage over the course of the experiment, *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
Fig. 3 CMS subtypes show distinct differences in caspase activation kinetics in response to co-treatment of Birinapant and chemotherapy. A, B Representative time-lapse images of Venus, TMRM and CFP/FRET emission ratio in HCT116 (A) cells stably expressing IETD-FRET probe (B) treated with 2 µM oxaliplatin/10 µM 5-FU/1 µM Birinapant for 48 h. Scale bar: 20 µm. C Overview of generation and interpretation of a single-cell trace extracted from time-lapse imaging of IETD-FRET probe cleavage in an HCT116 cell showing features of apoptosis in response to combination treatment. Cleavage of IETD substrate by caspases results in a disruption in FRET signal, which can be quantified by measuring CFP/FRET emission ratio. A mild increase in CFP/FRET emission ratio (I) before the loss of TMRM signal due to MOMP (II, red dashed line) indicates caspase-8-like activity (I–II, color coded as light blue). A rapid increase in CFP/FRET emission ratio (III) after the loss of TMRM signal indicates the involvement of executioner caspases (caspase-3 and -6) (II–III, color coded as light brown). D, E Representative single-cell CFP/FRET emission ratio kinetics of HCT116 (CMS1), RKO (CMS1), GP5D (CMS2), LS1034 (CMS2), LS513 (CMS3), and MDST8 (CMS4) cell lines treated with Oxa/5-FU, Birinapant, or combination of the drugs (D). Summary of the differences in caspase activation kinetics among CMS in response to co-treatment of Oxa/5-FU and Birinapant (E). F Quantification and comparison of the differences in caspase activation kinetics among CMS in response to Oxa/5-FU (left), Birinapant (middle), or combination of the drugs (right). “Onset of IETD cleavage” indicates a point of time at which cells start cleaving IETD substrate, “Duration of IETD cleavage” refers to a period of time between onset and end of IETD cleavage. Data are shown as individual values for each cell as well as the median ± quartiles. n = 146 cells were analyzed from at least three experiments per cell line. Statistical significance was tested using one-way ANOVA followed by Tukey’s multiple comparison test. “no substrate cleavage” indicates that cells did not exhibit an increase in IETD cleavage over the course of the experiment, *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.CC BY · PubMed Central
Fig. 4 Co-culture of colon cancer cell lines with healthy PBMCs. A Overview of the workflow. PBMCs were isolated using Ficoll-Hypaque density centrifugation, transferred in a cell culture transwell insert (0.4-µm pore size) and incubated for 5 days with the respective CRC cells. After 5 days, the insert with the PBMCs was transferred into a new well with newly seeded CRC cells. Following one day of co-culture, the cells were treated with 2 µM oxaliplatin/10 µM 5-FU/1 µM Birinapant for 2 days and analysed using an Annexin-V/PI assay. B–E Amount of apoptotic and necrotic cells after 48 h treatment in the absence (black) or presence (colored bar) of immune cells. The subtypes are represented by the colored bar with the CMS1 cell line HCT116 represented in orange (B), the CMS2 cell line GP5D in blue (C), CMS3 in pink (D, LS513), and the “CMS4” cell line MDST8 in green (E). Additionally, HCT116 (F) and GP5D (G) were co-incubated with TNFα-neutralizing antibodies during the treatments in co-culture. Significance was determined by multiple t tests using the Holm–Sidak method for multiple comparisons. N = 3; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
Fig. 4 Co-culture of colon cancer cell lines with healthy PBMCs. A Overview of the workflow. PBMCs were isolated using Ficoll-Hypaque density centrifugation, transferred in a cell culture transwell insert (0.4-µm pore size) and incubated for 5 days with the respective CRC cells. After 5 days, the insert with the PBMCs was transferred into a new well with newly seeded CRC cells. Following one day of co-culture, the cells were treated with 2 µM oxaliplatin/10 µM 5-FU/1 µM Birinapant for 2 days and analysed using an Annexin-V/PI assay. B–E Amount of apoptotic and necrotic cells after 48 h treatment in the absence (black) or presence (colored bar) of immune cells. The subtypes are represented by the colored bar with the CMS1 cell line HCT116 represented in orange (B), the CMS2 cell line GP5D in blue (C), CMS3 in pink (D, LS513), and the “CMS4” cell line MDST8 in green (E). Additionally, HCT116 (F) and GP5D (G) were co-incubated with TNFα-neutralizing antibodies during the treatments in co-culture. Significance was determined by multiple t tests using the Holm–Sidak method for multiple comparisons. N = 3; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.CC BY · PubMed Central
Fig. 5 Light-sheet microscopy images of representative cell lines grown in spheroids. HCT116 (A), GP5D (B, C), LS513 (D), and MDST8 (E) cells were grown in 3D spheroids and treated with the indicated treatments for 48 h, Hoechst-stained nuclei are displayed in grayscale and PI-stained in red. C shows an image taken on an inverted microscope with a 10× 0.3 NA objective and CCD camera and appropriate filters set for Hoechst and PI (Nikon TE 300 with Lumencor Sola II 365 and SPOT RT) as the spheroid broke-up following treatment and it was not possible to mount the debris for light-sheet fluorescence microscopy. The scale bar always indicates a length of 100 µm in the object space. Shown are representative images of three individual repeats.
Fig. 5 Light-sheet microscopy images of representative cell lines grown in spheroids. HCT116 (A), GP5D (B, C), LS513 (D), and MDST8 (E) cells were grown in 3D spheroids and treated with the indicated treatments for 48 h, Hoechst-stained nuclei are displayed in grayscale and PI-stained in red. C shows an image taken on an inverted microscope with a 10× 0.3 NA objective and CCD camera and appropriate filters set for Hoechst and PI (Nikon TE 300 with Lumencor Sola II 365 and SPOT RT) as the spheroid broke-up following treatment and it was not possible to mount the debris for light-sheet fluorescence microscopy. The scale bar always indicates a length of 100 µm in the object space. Shown are representative images of three individual repeats.CC BY · PubMed Central
Fig. 6 Gene expression profiles of key players involved in Birinapant adjuvant therapy from primary tumor tissue exhibit CMS subtype-specific patterns. Two independent CRC cohorts (Taxonomy and TCGA COAD-READ) were analyzed. Dotted line indicates a transition from linear to logarithmic space in the presence of outliers (see “Materials and methods”). Statistical analysis can be found in Supplementary File 2. Pairwise group comparisons were performed with Tukey HSD post hoc tests. P values were not adjusted for multiple comparisons as these analyses were considered exploratory. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
Fig. 6 Gene expression profiles of key players involved in Birinapant adjuvant therapy from primary tumor tissue exhibit CMS subtype-specific patterns. Two independent CRC cohorts (Taxonomy and TCGA COAD-READ) were analyzed. Dotted line indicates a transition from linear to logarithmic space in the presence of outliers (see “Materials and methods”). Statistical analysis can be found in Supplementary File 2. Pairwise group comparisons were performed with Tukey HSD post hoc tests. P values were not adjusted for multiple comparisons as these analyses were considered exploratory. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Cited by

See all 29

Metadata

Authors
Fichtner, M., Bozkurt, E., Salvucci, M., McCann, C., McAllister, K. A., Halang, L., Düssmann, H., Kinsella, S., Crawford, N., Sessler, T., Longley, D. B., & Prehn, J. H. M.
Affiliations
  • Royal College of Surgeons in Ireland (IE)
  • Queen's University Belfast (GB)
Corresponding author
Prehn, Jochen H. M.
Venue
Cell Death & Disease
Published
2020-11-30
Volume
11
Issue
11
Pages
1020-1020
ISSN
2041-4889 (ISSN-L)
OpenAlex
W3106549852
Cited by
28
References
64
Citations by year
2026: 2 · 2025: 4 · 2024: 7 · 2023: 7 · 2022: 5 · 2021: 3
FWCI
1.22
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Portal (Queen's University Belfast) (publishedVersion, cc-by)
  • Figshare (submittedVersion, cc-by)
Funders
Science Foundation Ireland (15/ERACSM/3268)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
birinapant, IAP antagonists, inhibitor of apoptosis proteins, colorectal cancer, consensus molecular subtypes, apoptosis, caspase-8, caspase-3, mitochondrial apoptosis, TNF-α, inflammatory signaling, patient stratification, cIAP1, cIAP2, XIAP
MeSH terms
Colonic Neoplasms, Dipeptides, Humans, Indoles, Apoptosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant. https://app.cochat.ai/papers/10.1038/s41419-020-03232-z
The paper
Fichtner, M., Bozkurt, E., Salvucci, M., McCann, C., McAllister, K. A., Halang, L., Düssmann, H., Kinsella, S., Crawford, N., Sessler, T., Longley, D. B., & Prehn, J. H. M. (2020). Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant. Cell Death & Disease. https://doi.org/10.1038/s41419-020-03232-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.